Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose for iron deficiency in paediatric inflammatory bowel disease
ACTRN12613000751774Phase 4Not yet recruiting
- Sponsor
- The Royal Children's Hospital
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ferric carboxymaltose in iron deficiency anemia (IDA), sponsored by The Royal Children's Hospital. Primary endpoints: Safety and efficacy of ferric carboxymaltose and Improvement in cognitive function and quality of life. Planned start Aug 2013; status: not yet recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on ACTRN12613000751774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000751774.